Clinlogix, a clinical research organization located just outside Philadelphia, is proud to announce its selection by the UPstart program at the University of Pennsylvania as a preferred Clinical Research Organization. The UPstart program strives to maximize the potential of University of Pennsylvania research and technologies through the creation and stimulus of entrepreneurial endeavors. Clinlogix is extremely excited about this partnership, which allows the company to leverage its extensive clinical and regulatory experience and transfer that knowledge to a variety of UPSTART projects.
Michael Poisel, UPstart Director, stated that “So much of the success of our UPstart companies is determined by the involvement of our many partners along the way. We are excited to have the Clinlogix team join us and add their significant experience in the development of these exciting young businesses.”
JeanMarie Markham, President and CEO of Clinlogix, stated that “The relevance of this relationship is the recognition that early stage, academic research is beginning to think beyond its borders. Historically there have been challenges in the process of ‘translating’ academic research and concepts into a ‘commercial’ product and viable company. The selection of Clinlogix by UPstart reflects the organization’s forward thinking. UPstart is beginning with the end in mind. With limited financial resources, the goal is to make the most impact by developing viable strategic development plans. “
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.